Drugs / KY-0301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06928363 | May 2025 → Nov 2027 expected | cancer | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KY-0301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06928363 ↗ |
| Modality | Other / unclassified | “antibody-drug conjugate (ADC)” NCT06928363 ↗ |
| Route | Intravenous | “i.v. Q2W” NCT06928363 ↗ |
| Target | EGFR | “targeting both EGFR and c-Met” NCT06928363 ↗ |